Blocan - General Information
A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Pharmacology of Blocan
Methscopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Methscopolamine has many uses including the prevention of motion sickness. It is not clear how Methscopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Methscopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Methscopolamine also may work directly on the vomiting center. Methscopolamine must be taken before the onset of motion sickness to be effective.
Blocan for patients
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
Additional information about Blocan
Blocan Indication: Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness.
Mechanism Of Action: Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Methylscopolamine
Synonyms: Epoxymethamine Bromide; Epoxytropine Tropate Methylbromide; Hyoscine Methobromide; Hyoscine Methylbromide; Lescopine Bromide; N-Methylscopolammonium Bromide; N-Methylscopolamine Methylsulfate; N-Methylhyoscine Bromide; Methylscopolamine Hydrobromide; Methylscopolamine Bromide; Methscopolamine Methylbromide; Methscopolamine; Methoscopylamine Bromide; Scopolamine Methobromide; Scopolamine Methylbromide; Scopolamin Methylbromide
Drug Category: Antispasmodics; Anticholinergic Agents; Parasympatholytics
Drug Type: Small Molecule; Approved
Absorption: Poorly and unreliably absorbed, total absorption is 10-25%.
Toxicity (Overdose): Symptoms of a methscopolamine overdose include headache, nausea, vomiting, dry mouth, difficulty swallowing, blurred vision, dilated pupils, hot, dry skin, dizziness; drowsiness, confusion, anxiety, seizures, weak pulse, and an irregular heartbeat. In addition, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
Protein Binding: Not Available
Biotransformation: Little is known about the fate and excretion of methscopolamine.
Half Life: Not Available
Dosage Forms of Blocan: Not Available
Chemical IUPAC Name: Not Available
Chemical Formula: C18H24NO4+
Methylscopolamine on Wikipedia: https://en.wikipedia.org/wiki/Methylscopolamine
Organisms Affected: Humans and other mammals